BR112018014222A2 - método de tratamento da glomerulopatia c3 - Google Patents
método de tratamento da glomerulopatia c3Info
- Publication number
- BR112018014222A2 BR112018014222A2 BR112018014222-0A BR112018014222A BR112018014222A2 BR 112018014222 A2 BR112018014222 A2 BR 112018014222A2 BR 112018014222 A BR112018014222 A BR 112018014222A BR 112018014222 A2 BR112018014222 A2 BR 112018014222A2
- Authority
- BR
- Brazil
- Prior art keywords
- glomerulopathy
- treatment method
- human
- susceptible
- administering
- Prior art date
Links
- 208000029574 C3 glomerulopathy Diseases 0.000 title abstract 2
- 208000027134 non-immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 title abstract 2
- 229940126681 complement 5a receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Abstract
a presente invenção refere-se a métodos de tratamento de um ser humano que sofre de ou está suscetível à glomerulopatia c3 compreendendo administrar ao ser humano uma quantidade eficaz de um antagonista de c5ar.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122024002810-7A BR122024002810A2 (pt) | 2016-01-14 | 2017-01-12 | Usos de composto antagonista de c5ar |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662278788P | 2016-01-14 | 2016-01-14 | |
US62/278,788 | 2016-01-14 | ||
US201662280346P | 2016-01-19 | 2016-01-19 | |
US62/280,346 | 2016-01-19 | ||
US201662347450P | 2016-06-08 | 2016-06-08 | |
US62/347,450 | 2016-06-08 | ||
US201662397527P | 2016-09-21 | 2016-09-21 | |
US62/397,527 | 2016-09-21 | ||
PCT/US2017/013132 WO2017123716A1 (en) | 2016-01-14 | 2017-01-12 | Method of treating c3 glomerulopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018014222A2 true BR112018014222A2 (pt) | 2018-12-11 |
Family
ID=59312069
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122024002810-7A BR122024002810A2 (pt) | 2016-01-14 | 2017-01-12 | Usos de composto antagonista de c5ar |
BR112018014222-0A BR112018014222A2 (pt) | 2016-01-14 | 2017-01-12 | método de tratamento da glomerulopatia c3 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122024002810-7A BR122024002810A2 (pt) | 2016-01-14 | 2017-01-12 | Usos de composto antagonista de c5ar |
Country Status (17)
Country | Link |
---|---|
US (3) | US20170202821A1 (pt) |
EP (1) | EP3402486A4 (pt) |
JP (3) | JP7339733B2 (pt) |
KR (1) | KR20180102642A (pt) |
CN (1) | CN108601790A (pt) |
AU (1) | AU2017207359C1 (pt) |
BR (2) | BR122024002810A2 (pt) |
CA (1) | CA3010735C (pt) |
IL (1) | IL260539B (pt) |
MA (1) | MA43872A (pt) |
MX (2) | MX2022006069A (pt) |
NZ (1) | NZ744083A (pt) |
RU (1) | RU2742888C2 (pt) |
SG (1) | SG11201805828YA (pt) |
TW (1) | TWI791423B (pt) |
WO (1) | WO2017123716A1 (pt) |
ZA (1) | ZA201804513B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA32975B1 (fr) | 2008-12-22 | 2012-01-02 | Chemocentryx Inc | Antagonistes de c5ar |
SI2585064T1 (sl) | 2010-06-24 | 2017-08-31 | Chemocentryx, Inc. | Antagonisti C5AR |
EP3200791B1 (en) | 2014-09-29 | 2020-04-22 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
AU2017207359C1 (en) | 2016-01-14 | 2022-09-01 | Chemocentryx, Inc. | Method of treating C3 glomerulopathy |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
AU2018227849B2 (en) | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
EP3658657A1 (en) * | 2017-07-27 | 2020-06-03 | Procter & Gamble International Operations SA. | Phase-stable, sprayable freshening compositions comprising suspended particles |
JP2021525860A (ja) * | 2018-05-25 | 2021-09-27 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 補体代替経路関連腎症バイオマーカー |
WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
EP3847174A4 (en) | 2018-09-06 | 2022-06-15 | Achillion Pharmaceuticals, Inc. | MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS |
AU2019346464A1 (en) | 2018-09-25 | 2021-04-08 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor D inhibitors |
PT3886820T (pt) | 2018-11-30 | 2023-05-24 | Chemocentryx Inc | Formulações de cápsulas |
MX2023001504A (es) * | 2020-08-07 | 2023-04-27 | Kira Pharmaceuticals Suzhou Ltd | Compuestos como inhibidores del receptor del componente complemento 5a (c5ar). |
JP2024500752A (ja) * | 2020-12-21 | 2024-01-10 | ケモセントリックス, インコーポレイテッド | C5a阻害剤を用いたc3糸球体腎症の治療 |
CN115192563B (zh) * | 2022-05-09 | 2023-10-13 | 北京大学第一医院 | C3a/C3aR通路拮抗剂治疗原发性膜性肾病的用途 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
CA2342251A1 (en) | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
RU2197288C2 (ru) * | 1999-08-03 | 2003-01-27 | Тверская медицинская академия | Способ лечения больных хроническим гломерулонефритом |
AU2001259511A1 (en) | 2000-05-05 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
JP5059275B2 (ja) | 2000-08-10 | 2012-10-24 | 田辺三菱製薬株式会社 | 新規3置換尿素誘導体およびその医薬としての用途 |
ATE509904T1 (de) | 2000-09-14 | 2011-06-15 | Mitsubishi Tanabe Pharma Corp | Neue amidverbindungen und deren medizinische verwendung |
DE60039921D1 (de) | 2000-09-29 | 2008-09-25 | Neurogen Corp | Hochaffine kleinmolekülige c5a-rezeptor-modulatoren |
EP1425042B2 (en) | 2001-08-17 | 2016-02-10 | Genentech, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
EA007576B1 (ru) | 2001-09-21 | 2006-12-29 | Мицубиси Фарма Корпорейшн | Производные 3-замещенных 4-пиримидонов |
ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
EP1487796A4 (en) | 2002-03-28 | 2005-11-16 | Neurogen Corp | SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR |
EP1487798A4 (en) | 2002-03-28 | 2005-07-13 | Neurogen Corp | Substituted tetrahydroisoquinolines as C5A receptor modulators |
JP2005530719A (ja) | 2002-03-29 | 2005-10-13 | ニューロジェン コーポレーション | 病原性炎症要素を有する状態の治療のための組み合わせ療法 |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
JP2005536533A (ja) | 2002-08-08 | 2005-12-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換ベンゾイミダゾール化合物 |
AU2003265625A1 (en) | 2002-08-21 | 2004-03-11 | Neurogen Corporation | Amino methyl imidazoles as c5a receptor modulators |
FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2004043223A2 (en) | 2002-11-05 | 2004-05-27 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
WO2004043925A2 (en) | 2002-11-08 | 2004-05-27 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
BRPI0410630A (pt) | 2003-06-19 | 2006-06-13 | Pfizer Prod Inc | antagonista de nk1 |
US20060154917A1 (en) | 2003-07-03 | 2006-07-13 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
EP1758580A4 (en) | 2004-06-24 | 2008-01-16 | Incyte Corp | N-SUBSTITUTED PIPERIDINE AND ITS USE AS A MEDICAMENT |
WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
AU2006215399B2 (en) | 2005-02-18 | 2010-12-09 | Astrazeneca Ab | Antibacterial piperidine derivatives |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007051062A2 (en) | 2005-10-28 | 2007-05-03 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
RS55192B1 (sr) | 2005-11-24 | 2017-01-31 | Dompé Farm S P A | Derivati (r)-arilkilamina i farmaceutske kompozicije koje ih sadrže |
KR20140057635A (ko) | 2006-03-15 | 2014-05-13 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료 |
WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
EP2077842A2 (en) * | 2006-10-31 | 2009-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an egfr antagonist for the treatment of glomerolonephritis |
WO2009004650A1 (en) | 2007-06-29 | 2009-01-08 | Torrent Pharmaceuticals Ltd. | Novel substituted piperidones as hsp inducers |
AU2009282480B2 (en) | 2008-08-11 | 2015-05-07 | Children's Medical Center Corporation | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
EP2331561A4 (en) | 2008-09-03 | 2013-02-27 | Xenome Ltd | PEPTIDE CONJUGATE LIBRARIES AND METHODS OF MAKING SAME |
US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
EP3101031A1 (en) | 2008-11-10 | 2016-12-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
MA32975B1 (fr) | 2008-12-22 | 2012-01-02 | Chemocentryx Inc | Antagonistes de c5ar |
US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
WO2011035143A2 (en) | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Methods and compositions for inhibiting rho-mediated diseases and conditions |
SI2585064T1 (sl) | 2010-06-24 | 2017-08-31 | Chemocentryx, Inc. | Antagonisti C5AR |
US8147400B1 (en) * | 2011-01-17 | 2012-04-03 | Coloplast A/S | Penile implant with dilatant liquid |
EP2864322B1 (en) * | 2012-06-20 | 2016-04-27 | Novartis AG | Complement pathway modulators and uses thereof |
CN105392803B (zh) | 2013-05-08 | 2019-12-06 | 诺和诺德股份有限公司 | C5aR拮抗剂的用途 |
EP3200791B1 (en) | 2014-09-29 | 2020-04-22 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
AU2017207359C1 (en) | 2016-01-14 | 2022-09-01 | Chemocentryx, Inc. | Method of treating C3 glomerulopathy |
CN109310686B (zh) | 2016-04-04 | 2022-06-21 | 凯莫森特里克斯股份有限公司 | 可溶性C5aR拮抗剂 |
JP2024500752A (ja) | 2020-12-21 | 2024-01-10 | ケモセントリックス, インコーポレイテッド | C5a阻害剤を用いたc3糸球体腎症の治療 |
-
2017
- 2017-01-12 AU AU2017207359A patent/AU2017207359C1/en active Active
- 2017-01-12 MX MX2022006069A patent/MX2022006069A/es unknown
- 2017-01-12 JP JP2018536408A patent/JP7339733B2/ja active Active
- 2017-01-12 US US15/404,610 patent/US20170202821A1/en not_active Abandoned
- 2017-01-12 MX MX2018008624A patent/MX2018008624A/es unknown
- 2017-01-12 CN CN201780006962.XA patent/CN108601790A/zh active Pending
- 2017-01-12 CA CA3010735A patent/CA3010735C/en active Active
- 2017-01-12 SG SG11201805828YA patent/SG11201805828YA/en unknown
- 2017-01-12 WO PCT/US2017/013132 patent/WO2017123716A1/en active Application Filing
- 2017-01-12 EP EP17738902.0A patent/EP3402486A4/en active Pending
- 2017-01-12 NZ NZ744083A patent/NZ744083A/en unknown
- 2017-01-12 MA MA043872A patent/MA43872A/fr unknown
- 2017-01-12 BR BR122024002810-7A patent/BR122024002810A2/pt unknown
- 2017-01-12 RU RU2018129378A patent/RU2742888C2/ru active
- 2017-01-12 TW TW106100938A patent/TWI791423B/zh active
- 2017-01-12 KR KR1020187023360A patent/KR20180102642A/ko active Search and Examination
- 2017-01-12 BR BR112018014222-0A patent/BR112018014222A2/pt active Search and Examination
-
2018
- 2018-07-06 ZA ZA2018/04513A patent/ZA201804513B/en unknown
- 2018-07-11 IL IL260539A patent/IL260539B/en active IP Right Grant
- 2018-11-08 US US16/184,535 patent/US11285138B2/en active Active
-
2021
- 2021-08-06 JP JP2021129774A patent/JP2021183625A/ja active Pending
-
2022
- 2022-02-14 US US17/670,604 patent/US11779576B2/en active Active
-
2023
- 2023-06-20 JP JP2023100664A patent/JP2023126235A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2018129378A3 (pt) | 2020-05-20 |
CN108601790A (zh) | 2018-09-28 |
EP3402486A4 (en) | 2019-08-28 |
RU2018129378A (ru) | 2020-02-14 |
CA3010735C (en) | 2023-06-13 |
US20220354837A1 (en) | 2022-11-10 |
CA3010735A1 (en) | 2017-07-20 |
KR20180102642A (ko) | 2018-09-17 |
AU2017207359A1 (en) | 2018-07-26 |
AU2017207359B2 (en) | 2022-04-14 |
US20190201388A1 (en) | 2019-07-04 |
MA43872A (fr) | 2021-05-19 |
JP2021183625A (ja) | 2021-12-02 |
US11779576B2 (en) | 2023-10-10 |
US11285138B2 (en) | 2022-03-29 |
US20170202821A1 (en) | 2017-07-20 |
BR122024002810A2 (pt) | 2024-03-12 |
JP2023126235A (ja) | 2023-09-07 |
EP3402486A1 (en) | 2018-11-21 |
AU2017207359C1 (en) | 2022-09-01 |
JP7339733B2 (ja) | 2023-09-06 |
MX2018008624A (es) | 2018-12-10 |
SG11201805828YA (en) | 2018-08-30 |
JP2019501935A (ja) | 2019-01-24 |
MX2022006069A (es) | 2023-01-12 |
WO2017123716A1 (en) | 2017-07-20 |
TWI791423B (zh) | 2023-02-11 |
ZA201804513B (en) | 2024-01-31 |
NZ744083A (en) | 2022-07-01 |
RU2742888C2 (ru) | 2021-02-11 |
IL260539B (en) | 2021-05-31 |
TW201726134A (zh) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018014222A2 (pt) | método de tratamento da glomerulopatia c3 | |
CY1122603T1 (el) | Γαμμα-δικετονες για τη θεραπευτικη αντιμετωπιση και την προληψη της γηρανσης του δερματος και των ρυτιδων | |
CL2020002019A1 (es) | Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582) | |
WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
MA46098A (fr) | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r | |
BR112017015059A2 (pt) | inibidor de proteassoma e uso | |
PH12019500204A1 (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
BR112017008093A2 (pt) | processos para tratamento de doenças oculares | |
EA201890394A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ | |
MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
MY194586A (en) | Anti-garp antibody | |
BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
BR112017003571A2 (pt) | terapia combinada | |
EA201791095A1 (ru) | Способ лечения рака | |
EA036102B9 (ru) | Терапевтические средства с углевод-опосредованной адресной доставкой | |
MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
BR112019005539A2 (pt) | métodos de tratamento de lesão renal aguda | |
MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
BR112018071467A2 (pt) | método de tratamento ou prevenção de patologias hepáticas | |
BR112017013674A2 (pt) | métodos e composições para tratamento de doenças cerebrais. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024002810-7 PROTOCOLO 870240011932 EM 09/02/2024 17:43. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |